Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06212271 · ClinicalTrials.gov registry record · Early Phase 1
Mechanistic Clinical Trial of Colchicine in Patients With Peripheral Artery Disease
A Early Phase 1 study of Peripheral Artery Disease, sponsored by University of Pennsylvania.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06212271 is a Early Phase 1 study of Peripheral Artery Disease that is actively recruiting participants, run by University of Pennsylvania. The registered enrollment target is 24 participants, below the 126-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06212271, a Early Phase 1 study of Peripheral Artery Disease, is actively recruiting participants, sponsored by University of Pennsylvania.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this mechanistic clinical trial is to test the effects of reducing inflammatory signaling in femoral artery atherosclerotic plaques. Researchers will compare patients receiving colchicine to patients receiving placebo to determine the effect of colchicine on the inflammatory state of atherosclerotic femoral arteries.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Colchicine
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-09-25 |
| Est. Completion | 2026-04 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06212271
The ClinicalTrials.gov registry entry for NCT06212271 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 126-participant average among 50 other Peripheral Artery Disease trials with a reported enrollment target (81% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peripheral Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06212271 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06212271 about?
NCT06212271 is a clinical study titled "Mechanistic Clinical Trial of Colchicine in Patients With Peripheral Artery Disease". The goal of this mechanistic clinical trial is to test the effects of reducing inflammatory signaling in femoral artery atherosclerotic plaques. Researchers will compare patients receiving colchicine to patients receiving placebo to determine the effect of colchicine on the inflammatory state of ath...
What is the current status of trial NCT06212271?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2024-09-25. Estimated completion is 2026-04.
What conditions does trial NCT06212271 study?
This clinical trial studies the following conditions: Peripheral Artery Disease.
What interventions are being tested in trial NCT06212271?
The interventions under investigation include: Placebo (DRUG), Colchicine (DRUG).
Who is sponsoring clinical trial NCT06212271?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06212271 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease
RECRUITING · Early Phase 1
-
Response to Exercise and Nitric Oxide in PAD
RECRUITING · Phase 2
-
The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication
RECRUITING · Phase 1
-
Improving Mobility After Revascularization in Peripheral Artery Disease
RECRUITING · Phase 3
-
The Effects of a Novel, Non-ischemic and Pain-free Exercise Intervention in Peripheral Artery Disease
RECRUITING · NA
-
BEETroot Juice to Reverse Functional Impairment in PAD
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.